Loading organizations...
§ Private Profile · Quebec, QC, Canada
Biotechnology company designing therapies for autoimmune and demyelinating diseases, focused on precision-targeting membrane receptors.
Launched in 2020, Find Therapeutics is a venture capital-funded biotechnology company that designs ground-breaking therapies for patients with autoimmune and demyelinating diseases through the precision-targeting of membrane receptors. The organization focuses on advancing a pipeline of novel drug candidates, highlighted by its primary asset FTX-101, which recently entered Phase 1 clinical trials with its first human subject dosed. To support its ongoing clinical development and research operations, the enterprise secured $8.1 million, or approximately CAD$11 million, in convertible note financing. This crucial financial backing was provided by a strong syndicate of institutional investors that includes CTI Life Sciences, adMare BioInnovations, Domain Therapeutics, and Investissement Québec. Additionally, the growing firm utilizes foundational technology originating from Peptimimesis Pharma and recently expanded its strategic leadership by adding industry experts Nancy Messier and Thierry Abribat to its board of directors.
Find Therapeutics has raised $7.2M across 1 funding round.
Find Therapeutics has raised $7.2M in total across 1 funding round.
Find Therapeutics has raised $7.2M in total across 1 funding round.
Find Therapeutics's investors include adMare BioInnovations, CTI Life Sciences Fund, Investissement Québec.
Find Therapeutics has raised $7.2M across 1 funding round. Most recently, it raised $7.2M Series A Extension in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 9, 2026 | $7.2M Series A Plus | — | Admare Bioinnovations, CTI Life Sciences Fund, Investissement Québec | Announced |